Related Experiment Video
Updated: Jun 20, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Hypoglycemics: pharmacokinetic considerations during pregnancy
Chagit Klieger1, Erika Pollex, Aleksey Kazmin
1Motherisk Program, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children and The University of Toronto, Toronto, Ontario, Canada. chagit.klieger@gmail.com
Therapeutic Drug Monitoring
|September 5, 2009
Summary
Pregnancy alters how antidiabetic drugs work, affecting their safety and efficacy. More research is needed on how these medications cross the placenta to ensure safe treatment for gestational diabetes.
Area of Science:
- Pharmacology
- Obstetrics
- Endocrinology
Background:
- Pregnancy involves significant physiological and hormonal changes, particularly from the first to the last trimester.
- These changes can alter drug pharmacokinetics and pharmacodynamics, impacting medication safety and efficacy.
- Gestational diabetes affects approximately 5% of pregnant women, necessitating safe and effective treatment options.
Purpose of the Study:
- To review common antidiabetic drugs used during pregnancy.
- To focus on pharmacokinetic considerations crucial for treatment decisions.
- To highlight the need for further research on drug transfer across the placenta.
Main Methods:
- Review of existing literature on antidiabetic drug classes.
- Discussion of pharmacokinetic and pharmacodynamic alterations during pregnancy.
- Emphasis on in vitro placental perfusion studies, controlled trials, and cord blood measurements for assessing transplacental passage.
Main Results:
- Maternal and fetal responses to antidiabetic drugs are influenced by altered absorption, distribution, and elimination.
- The placenta plays a role in drug metabolism and elimination, affecting fetal exposure.
- Limited data exists on the extent of transplacental passage for many antidiabetic agents.
Conclusions:
- Pharmacokinetic considerations are vital for selecting antidiabetic drugs during pregnancy.
- Further studies are required to fully understand the safety profile and placental transfer of these medications.
- Integrated research approaches are necessary to clarify drug transport across the placenta.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...